HBI Deals+Insights / M&A/IPOs
The sale of Bridgepoint-owned international dialysis giant Diaverum is likley being delayed until the future of its lucrative Saudi contract is determined, as potential suitors adopt a wait and see approach, Healthcare Europa hears.